Manufacturer of Controlled Substances; Notice of Application

---
identifier: "/us/fr/E8-7039"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Manufacturer of Controlled Substances; Notice of Application"
title_number: 0
title_name: "Federal Register"
section_number: "E8-7039"
section_name: "Manufacturer of Controlled Substances; Notice of Application"
positive_law: false
currency: "2008-04-04"
last_updated: "2008-04-04"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "E8-7039"
document_type: "notice"
publication_date: "2008-04-04"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "73 FR 18570"
fr_volume: 73
---


#  Manufacturer of Controlled Substances; Notice of Application

Pursuant to 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 10, 2008, Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug | Schedule |
| --- | --- |
| Dihydromorphine (9145) | I |
| Amphetamine (1100) | II |
| Methylphenidate (1724) | II |
| Amobarbital (2125) | II |
| Pentobarbital (2270) | II |
| Secobarbital (2315) | II |
| Glutethimide (2550) | II |
| Codeine (9050) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Hydrocodone (9193) | II |
| Methadone (9250) | II |
| Methadone intermediate (9254) | II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273) | II |
| Morphine (9300) | II |
| Oxymorphone (9652) | II |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 3, 2008.

Dated: March 28, 2008.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.